3 completed, 1 recruiting. 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Completed 3, Recruiting 1 |
Follow Emma Guttman: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Regeneron AA Multicenter (Dupilumab) Dupilumab, Placebo - Alopecia Areata | Phase 2 | Recruiting | Emma Guttman | 76 | 2023-04-10 | 2026-06-17 |
| Ritlecitinib for Cicatricial Alopecia PF-06651600 - Cicatricial Alopecia | Phase 2 | Completed | Emma Guttman | 50 | 2022-12-15 | 2026-07-15 |
| Dual JAK1/TYK2 Inhibitor for Cicatricial Alopecia PF-06700841, Placebo - Cicatricial Alopecia | Phase 2 | Completed | Emma Guttman | 51 | 2021-05-19 | 2026-05-19 |
| A Pilot Study of Tralokinumab in Subjects With Moderate to Severe Alopecia Areata Tralokinumab, Placebo - Alopecia Areata | Phase 2 | Completed | Emma Guttman | 22 | 2016-01-01 | 2020-01-07 |
Alopecia (3) · Alopecia Areata (2) · Alopecia universalis (1) · Lichen Planus (1)
PF-06651600 (1) · PF-06700841 (1) · dupilumab (1) · tralokinumab (1)
United States (4)
Emma Guttman-Yassky, MD, PhD (2)